China Viscosupplementation Market Size & Outlook
China viscosupplementation market, 2018-2030 (US$M)
Related Markets
China viscosupplementation market highlights
- The China viscosupplementation market generated a revenue of USD 321.2 million in 2023 and is expected to reach USD 636.2 million by 2030.
- The China market is expected to grow at a CAGR of 10.3% from 2024 to 2030.
- In terms of segment, single injection was the largest revenue generating product in 2023.
- Single Injection is the most lucrative product segment registering the fastest growth during the forecast period.
Viscosupplementation market data book summary
| Market revenue in 2023 | USD 321.2 million |
| Market revenue in 2030 | USD 636.2 million |
| Growth rate | 10.3% (CAGR from 2023 to 2030) |
| Largest segment | Single injection |
| Fastest growing segment | Single Injection |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Single Injection, Three Injection, Five Injection |
| Key market players worldwide | DePuy Synthes, Sanofi SA, Smith & Nephew PLC, Anika Therapeutics Inc, Zimmer Biomet Holdings Inc, Ferring, Lifecore Biomedical Inc, LG Chem, Roche Holding AG |
Other key industry trends
- In terms of revenue, China accounted for 6.7% of the global viscosupplementation market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan viscosupplementation market is projected to lead the regional market in terms of revenue in 2030.
- Australia is the fastest growing regional market in Asia Pacific and is projected to reach USD 115.5 million by 2030.
Single injection was the largest segment with a revenue share of 43.37% in 2023. Horizon Databook has segmented the China viscosupplementation market based on single injection, three injection, five injection covering the revenue growth of each sub-segment from 2018 to 2030.
According to an article published in Forbes magazine in 2017, China was the fastest aging country in the world, with a projection of 44% geriatric population by 2050. The aging population in the country is aggravating healthcare burden, especially pertaining to treatment of age-related diseases. The risk of osteoporosis is higher in people who are over 50 years.
In the year 2013, the population falling under this group was around 357 million. In 2013, the country had more than 85 million osteoarthritis patients. By 2025, total population of osteoporosis patients is expected to reach 1.39 billion in which more than 518 million are anticipated to be over 50.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Viscosupplementation Market Scope
Viscosupplementation Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China viscosupplementation market size, by product, 2018-2030 (US$M)
China Viscosupplementation Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
